PDF Cover

Niraparib Market

The market for Niraparib was estimated at $1.3 billion in 2024; it is anticipated to increase to $2.0 billion by 2030, with projections indicating growth to around $2.8 billion by 2035.

Report ID:DS1802409
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Niraparib
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Niraparib Market Outlook

Revenue, 2024

$1.3B

Forecast, 2034

$2.6B

CAGR, 2025 - 2034

7.1%

The Niraparib industry revenue is expected to be around $1.4 billion in 2025 and expected to showcase growth with 7.1% CAGR between 2025 and 2034. The market continues to gain strong commercial momentum due to the increasing adoption of precision oncology therapies and rising prevalence of ovarian and related gynecological cancers worldwide. Healthcare providers are increasingly emphasizing targeted cancer treatment strategies that improve progression free survival and support personalized patient care approaches. Growing awareness regarding genetic testing and biomarker driven oncology treatment is further strengthening demand for advanced PARP inhibitor therapies. In addition, pharmaceutical companies are expanding oncology research investments and strategic collaborations to broaden therapeutic applications and improve treatment accessibility. Supportive regulatory approvals, expanding reimbursement frameworks, and increasing integration of targeted oncology drugs into standard cancer treatment protocols continue to reinforce the long term relevance of niraparib across global healthcare markets.

Niraparib is an oral PARP inhibitor primarily used for the treatment and maintenance therapy of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The drug works by targeting DNA repair pathways in cancer cells, making it highly effective within biomarker driven precision oncology treatment frameworks. Its major applications include maintenance therapy following chemotherapy, recurrent cancer management, and combination treatment strategies within advanced oncology care programs. Rising demand for personalized cancer therapeutics and increasing use of genetic testing are significantly supporting market growth. Recent trends include expanded clinical investigations into broader oncology indications, growing adoption of combination therapies with immuno oncology agents, and increased investment in targeted cancer treatment innovation. Advancements in companion diagnostics and precision medicine technologies are further strengthening the commercial outlook for niraparib within the global oncology therapeutics industry.

Niraparib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Niraparib Market Outlook

Market Key Insights

  • The Niraparib market is projected to grow from $1.3 billion in 2024 to $2.6 billion in 2034. This represents a CAGR of 7.1%, reflecting rising demand across Ovarian Cancer Treatment, Prostate Cancer Management, and Breast Cancer Therapy.

  • GlaxoSmithKline, Tesaro Inc, Zejula are among the leading players in this market, shaping its competitive landscape.

  • U.S. and China are the top markets within the Niraparib market and are expected to observe the growth CAGR of 4.6% to 6.8% between 2024 and 2030.

  • Emerging markets including Nigeria, Indonesia and Colombia are expected to observe highest growth with CAGR ranging between 8.2% to 9.8%.

  • Transition like Transition from Broad Spectrum Chemotherapy to Precision Oncology Approaches has greater influence in U.S. and China market's value chain; and is expected to add $62 million of additional value to Niraparib industry revenue by 2030.

  • The Niraparib market is set to add $1.3 billion between 2024 and 2034, with manufacturer targeting Hospitals & Pharmacies Application projected to gain a larger market share.

  • With

    high demand in cancer therapies, and

    Technological Advancements in Drug Development, Niraparib market to expand 99% between 2024 and 2034.

niraparib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Niraparib - Country Share Analysis

Opportunities in the Niraparib

The growing availability of biomarker and genetic testing services presents a significant opportunity for the niraparib market. Healthcare systems are increasingly investing in precision medicine infrastructure to improve treatment selection and patient outcomes. Enhanced access to BRCA mutation testing and related genomic diagnostics is also helping identify suitable candidates for targeted therapies. This trend is particularly important in emerging healthcare markets where precision oncology adoption remains underpenetrated. Ovarian cancer maintenance therapy is expected to benefit the most, as improved diagnostic capabilities expand patient identification and strengthen demand for targeted PARP inhibitor treatments.

Growth Opportunities in North America and Asia-Pacific

North America represents the leading regional market for niraparib, supported by advanced oncology care infrastructure, widespread adoption of precision medicine, and strong access to genetic testing services. The region benefits from high awareness of targeted cancer therapies and well-established reimbursement frameworks for innovative oncology treatments. Key market drivers include increasing utilization of PARP inhibitors in ovarian cancer treatment, growing integration of biomarker-driven treatment selection, and continuous investment in cancer research. Significant opportunities exist in expanding applications for prostate cancer management, combination therapy development, and broader use of precision oncology approaches. The competitive landscape is characterized by the presence of major pharmaceutical companies offering PARP inhibitors and other targeted oncology drugs, resulting in strong competition for market share. Ongoing clinical research, regulatory support for innovative therapies, and expanding personalized medicine initiatives are expected to sustain demand and strengthen North America's position within the global niraparib market.
Asia-Pacific is emerging as a high-growth market for niraparib due to rising cancer incidence, improving healthcare infrastructure, and increasing adoption of advanced oncology treatments. Countries such as China, Japan, South Korea, and India are investing heavily in cancer diagnosis and treatment capabilities, supporting broader access to targeted therapies. Key growth drivers include expanding genetic testing availability, growing awareness of precision oncology, and government initiatives aimed at improving cancer care outcomes. Major opportunities are developing in ovarian cancer maintenance therapy and the expansion of PARP inhibitor use in genetically defined patient populations. Competition is intensifying as multinational pharmaceutical companies strengthen regional commercialization efforts while local healthcare systems improve access to innovative medicines. Increasing healthcare expenditure, expanding oncology treatment networks, and rising demand for personalized cancer therapies are expected to drive long-term growth across the Asia-Pacific niraparib market.

Market Dynamics and Supply Chain

01

Driver: Rising Precision Oncology Adoption and Expanding Genetic Testing Utilization

The increasing adoption of precision oncology is also a major driver of the niraparib market. Healthcare providers are also increasingly tailoring cancer treatments based on individual genetic profiles, creating greater demand for targeted therapies such as PARP inhibitors. Niraparib benefits from this trend by addressing tumors with deficiencies in DNA repair pathways. Simultaneously, the expanding use of genetic and biomarker testing is also strengthening patient identification and treatment selection. Advanced diagnostic technologies are also enabling clinicians to detect BRCA mutations and other homologous recombination repair abnormalities more efficiently, supporting the use of targeted therapies in appropriate patient populations. Growing integration of genomic medicine into oncology practice is also improving treatment personalization, expanding eligible patient groups, and reinforcing the commercial value of niraparib across multiple cancer indications.
The continued expansion of PARP inhibitor applications beyond traditional ovarian cancer treatment is also significantly supporting market growth. Ongoing clinical research and regulatory advancements are also increasing the use of niraparib in additional oncology indications, including prostate and breast cancer. This trend reflects a broader industry focus on extending targeted therapies into genetically defined patient populations across different tumor types. Pharmaceutical companies and research institutions are also actively conducting studies to evaluate new combination therapies and treatment settings. As evidence supporting broader therapeutic utility grows, niraparib is also expected to benefit from increased physician adoption, expanded treatment opportunities, and stronger market penetration within precision oncology.
02

Restraint: High Treatment Costs and Reimbursement Limitations Restrict Patient Access

One of the most significant restraints affecting the niraparib market is the high cost associated with long-term targeted cancer therapy. Treatment expenses can create affordability challenges for patients, healthcare systems, and insurers, particularly in emerging markets where reimbursement coverage may be limited. For example, patients lacking comprehensive insurance support may delay treatment initiation or seek alternative therapies. These financial barriers reduce the accessible patient population and can slow market penetration. As a result, revenue growth opportunities may be constrained in cost-sensitive regions, while pricing pressures continue to influence commercial strategies and overall market expansion.
03

Opportunity: China Oncology Market Expansion Driving Targeted Therapy Demand and Advanced Prostate Cancer Patients Creating New Niraparib Growth Opportunities

China offers substantial growth potential due to rising cancer incidence, expanding healthcare infrastructure, and increasing access to innovative oncology treatments. Government initiatives supporting advanced cancer care and precision medicine are improving the adoption environment for targeted therapies such as niraparib. Pharmaceutical partnerships, local commercialization strategies, and broader availability of genetic testing services are further enhancing market opportunities. Ovarian cancer treatment is expected to remain the largest application segment, while prostate cancer management presents additional growth potential. As precision oncology awareness increases, China is likely to emerge as a key regional growth market for niraparib.
Advanced prostate cancer represents a promising opportunity for niraparib as precision oncology gains wider acceptance. Increasing use of genomic profiling is enabling healthcare providers to identify patients with homologous recombination repair gene alterations who may benefit from PARP inhibitor therapy. Strategic clinical collaborations and expanding research programs are supporting broader adoption in metastatic castration-resistant prostate cancer settings. Combination treatment approaches are also attracting significant attention. Among all emerging applications, prostate cancer management is expected to be one of the fastest-growing segments as personalized treatment strategies become more integrated into routine oncology practice.
04

Challenge: Intense Competition from Alternative PARP Inhibitors and Targeted Therapies

The niraparib market faces growing competitive pressure from other PARP inhibitors and emerging targeted oncology treatments. Several competing therapies offer similar mechanisms of action and are supported by extensive clinical data across multiple cancer indications. For instance, physicians may choose alternative PARP inhibitors based on specific clinical evidence, treatment guidelines, pricing considerations, or patient preferences. Additionally, the development of next-generation targeted therapies and combination treatment approaches is increasing competition within the precision oncology landscape. This competitive environment can affect prescribing patterns, limit market share growth, and intensify efforts among manufacturers to differentiate products and maintain commercial performance.

Supply Chain Landscape

1

Raw Material Procurement

Yakima Chief HopsTotal Petrochemicals USA
2

API Production

Teva Active Pharmaceutical IngredientsPfizer Centers for Therapeutic Innovation
3

Formulation & Processing

GlaxoSmithKlineRocheSanofi
4

Distribution & End-users

WalgreensCVS HealthHospital Networks
Niraparib - Supply Chain

Use Cases of Niraparib in Ovarian Cancer Treatment & Prostate Cancer Management

Ovarian Cancer Treatment : Ovarian cancer treatment represents the largest application segment for niraparib, primarily through oral niraparib tablets used as maintenance therapy following a positive response to platinum-based chemotherapy. As a poly ADP-ribose polymerase inhibitor, niraparib helps prevent cancer recurrence by targeting DNA repair mechanisms in tumor cells. Its ability to provide maintenance treatment regardless of biomarker status has broadened patient eligibility compared to some targeted therapies. The therapy is widely adopted in recurrent and advanced ovarian cancer management due to its convenience as an oral treatment and its potential to extend progression-free survival, making it a critical component of modern ovarian cancer care.
Prostate Cancer Management : Prostate cancer management is an emerging application area for niraparib, particularly in advanced and metastatic castration-resistant prostate cancer. Oral niraparib tablets are commonly utilized in combination therapy approaches for patients with specific genetic alterations related to homologous recombination repair pathways. The treatment works by exploiting deficiencies in cancer cell DNA repair mechanisms, helping to slow disease progression. Increasing adoption of precision oncology and genetic testing has expanded opportunities for targeted therapies such as niraparib in prostate cancer care. Its role within personalized treatment strategies is strengthening as healthcare providers seek more effective options for managing advanced-stage disease.
Breast Cancer Therapy : Breast cancer therapy represents a developing application segment for niraparib, supported by ongoing clinical research evaluating its effectiveness in selected patient populations. Oral niraparib formulations are primarily investigated for patients with inherited or acquired DNA repair deficiencies, including certain BRCA-mutated breast cancers. The therapy's mechanism of disrupting cancer cell DNA repair pathways offers potential benefits in targeted treatment settings where conventional therapies may have limited effectiveness. Growing interest in personalized medicine and biomarker-driven treatment selection is increasing attention toward PARP inhibitors in breast cancer management. Continued clinical development and expanding understanding of genomic oncology are expected to support future adoption within this therapeutic area.

Impact of Industry Transitions on the Niraparib Market

As a core segment of the Pharmaceutical industry, the Niraparib market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Broad Spectrum Chemotherapy to Precision Oncology Approaches and Transition from Single Indication Therapies to Multi Cancer Applications have redefined priorities across the Pharmaceutical sector, influencing how the Niraparib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Broad Spectrum Chemotherapy to Precision Oncology Approaches

The niraparib industry is benefiting from the broader transition from conventional chemotherapy-based treatment strategies toward precision oncology. Healthcare providers increasingly utilize targeted therapies that are matched to specific genetic and molecular characteristics of patients, improving treatment personalization. For example, genetic testing is now routinely incorporated into oncology care pathways to identify patients who may benefit from PARP inhibitor therapies such as niraparib. This transition is influencing the pharmaceutical and diagnostics industries by increasing demand for companion testing services, biomarker-driven treatment selection, and specialized oncology products, thereby creating a more personalized and data-driven cancer treatment ecosystem.
02

Transition from Single Indication Therapies to Multi Cancer Applications

A significant industry transition is the expansion of targeted oncology drugs from single-disease applications toward broader use across multiple cancer types. Niraparib was initially associated primarily with ovarian cancer management, but ongoing clinical development has increased interest in prostate cancer and breast cancer applications. For instance, pharmaceutical companies are investing in research programs that evaluate PARP inhibitors across genetically defined patient populations rather than focusing on one tumor type alone. This transition is reshaping oncology drug development strategies, encouraging cross-indication commercialization opportunities, and expanding collaboration between pharmaceutical manufacturers, research institutions, and healthcare providers.